Literature DB >> 26671996

Profiling Non-Small Cell Lung Cancer: From Tumor to Blood.

Dana W Y Tsui1, Michael F Berger2.   

Abstract

Circulating cell-free tumor DNA has shown great promise for noninvasive genomic profiling to guide the administration of targeted therapies in non-small cell lung cancer. With advancements in molecular technology, it is now possible to interrogate multiple clinically actionable genetic drivers in the blood with a single assay. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Year:  2015        PMID： 26671996      PMCID： PMC4852855          DOI： 10.1158/1078-0432.CCR-15-2514

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  Chipping away at the lung cancer genome.

Authors:  William Pao; Katherine E Hutchinson
Journal:  Nat Med       Date:  2012-03-06       Impact factor: 53.440

2.  Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.

Authors:  Hideharu Kimura; Kazuo Kasahara; Makoto Kawaishi; Hideo Kunitoh; Tomohide Tamura; Brian Holloway; Kazuto Nishio
Journal:  Clin Cancer Res       Date:  2006-07-01       Impact factor: 12.531

3.  Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.

Authors:  Juliann Chmielecki; Jasmine Foo; Geoffrey R Oxnard; Katherine Hutchinson; Kadoaki Ohashi; Romel Somwar; Lu Wang; Katherine R Amato; Maria Arcila; Martin L Sos; Nicholas D Socci; Agnes Viale; Elisa de Stanchina; Michelle S Ginsberg; Roman K Thomas; Mark G Kris; Akira Inoue; Marc Ladanyi; Vincent A Miller; Franziska Michor; William Pao
Journal:  Sci Transl Med       Date:  2011-07-06       Impact factor: 17.956

4.  Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.

Authors:  Tony Mok; Yi-Long Wu; Jin Soo Lee; Chong-Jen Yu; Virote Sriuranpong; Jennifer Sandoval-Tan; Guia Ladrera; Sumitra Thongprasert; Vichien Srimuninnimit; Meilin Liao; Yunzhong Zhu; Caicun Zhou; Fatima Fuerte; Benjamin Margono; Wei Wen; Julie Tsai; Matt Truman; Barbara Klughammer; David S Shames; Lin Wu
Journal:  Clin Cancer Res       Date:  2015-03-31       Impact factor: 12.531

Review 5.  Circulating tumor DNA as a liquid biopsy for cancer.

Authors:  Ellen Heitzer; Peter Ulz; Jochen B Geigl
Journal:  Clin Chem       Date:  2014-11-11       Impact factor: 8.327

6.  Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.

Authors:  Yanan Kuang; Andrew Rogers; Beow Y Yeap; Lilin Wang; Mike Makrigiorgos; Kristi Vetrand; Sara Thiede; Robert J Distel; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

7.  Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients.

Authors:  Tony K F Yung; K C Allen Chan; Tony S K Mok; Joanna Tong; Ka-Fai To; Y M Dennis Lo
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

8.  Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.

Authors:  Geoffrey R Oxnard; Cloud P Paweletz; Yanan Kuang; Stacy L Mach; Allison O'Connell; Melissa M Messineo; Jason J Luke; Mohit Butaney; Paul Kirschmeier; David M Jackman; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2014-01-15       Impact factor: 12.531

9.  Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.

Authors:  Cloud P Paweletz; Adrian G Sacher; Chris K Raymond; Ryan S Alden; Allison O'Connell; Stacy L Mach; Yanan Kuang; Leena Gandhi; Paul Kirschmeier; Jessie M English; Lee P Lim; Pasi A Jänne; Geoffrey R Oxnard
Journal:  Clin Cancer Res       Date:  2015-10-12       Impact factor: 12.531

10.  Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.

Authors:  Jean-Yves Douillard; Gyula Ostoros; Manuel Cobo; Tudor Ciuleanu; Rebecca Cole; Gael McWalter; Jill Walker; Simon Dearden; Alan Webster; Tsveta Milenkova; Rose McCormack
Journal:  J Thorac Oncol       Date:  2014-09       Impact factor: 15.609
View more
  5 in total

Review 1.  Pathologists and liquid biopsies: to be or not to be?

Authors:  Paul Hofman; Helmut H Popper
Journal:  Virchows Arch       Date:  2016-08-23       Impact factor: 4.064

2.  Molecular biology tools for precision medicine in managing lung cancer.

Authors:  P A Mahesh
Journal:  Lung India       Date:  2018 Jan-Feb

3.  Distribution of circulating tumor DNA in lung cancer: analysis of the primary lung and bone marrow along with the pulmonary venous and peripheral blood.

Authors:  Taichiro Goto; Yosuke Hirotsu; Kenji Amemiya; Takahiro Nakagomi; Daichi Shikata; Yujiro Yokoyama; Kenichiro Okimoto; Toshio Oyama; Hitoshi Mochizuki; Masao Omata
Journal:  Oncotarget       Date:  2017-07-25

Review 4.  Emerging non-invasive detection methodologies for lung cancer.

Authors:  Zhen Li; Jinian Shu; Bo Yang; Zuojian Zhang; Jingyun Huang; Yang Chen
Journal:  Oncol Lett       Date:  2020-03-12       Impact factor: 2.967

5.  Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.

Authors:  Moom R Roosan; Isa Mambetsariev; Rebecca Pharaon; Jeremy Fricke; Hatim Husain; Karen L Reckamp; Marianna Koczywas; Erminia Massarelli; Andrea H Bild; Ravi Salgia
Journal:  Chest       Date:  2021-04-18       Impact factor: 9.410
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.